CAJ | 학술논문

目的：探讨血清人附睾蛋白4（HE4）、糖类抗原125（CA125）和细胞角蛋白19片段（CYFRA21-1）联合检测对卵巢癌诊断的临床价值。方法选择卵巢癌患者85例、卵巢良性肿瘤患者85例和健康妇女（正常对照组）85名，采用酶联免疫吸附试验（ELISA）检测血清 HE4水平，采用化学发光法检测血清 CA125、CYFRA21-l水平，比较各组3项指标的检测结果并计算阳性率及联合检测的阳性率。结果卵巢癌组血清 HE4、CA125和CYFRA21-1水平明显高于卵巢良性肿瘤组和正常对照组（P ＜0．01）。卵巢癌组 HE4、CA125和 CYFRA21-1的阳性率分别为88．24％、74．12％和77．65％，三者联合检测的阳性率为98．82％。结论HE4、CA125和 CYFRA21-1联合检测对卵巢癌具有良好的辅助诊断价值。
목적：탐토혈청인부고단백4（HE4）、당류항원125（CA125）화세포각단백19편단（CYFRA21-1）연합검측대란소암진단적림상개치。방법선택란소암환자85례、란소량성종류환자85례화건강부녀（정상대조조）85명，채용매련면역흡부시험（ELISA）검측혈청 HE4수평，채용화학발광법검측혈청 CA125、CYFRA21-l수평，비교각조3항지표적검측결과병계산양성솔급연합검측적양성솔。결과란소암조혈청 HE4、CA125화CYFRA21-1수평명현고우란소량성종류조화정상대조조（P ＜0．01）。란소암조 HE4、CA125화 CYFRA21-1적양성솔분별위88．24％、74．12％화77．65％，삼자연합검측적양성솔위98．82％。결론HE4、CA125화 CYFRA21-1연합검측대란소암구유량호적보조진단개치。
Objective To investigate the clinical significance of human epididymis 4 (HE4),carbohydrate antigen 125 (CA125 )and cytokeratin-19-fragment (CYFRA21-1 )combined detection in the diagnosis of malignant ovarian tumor.Methods The sera of 85 patients with malignant ovarian tumor,85 patients with benign ovarian tumor and 85 healthy women (healthy control group)were collected.The serum levels of HE4 were determined by enzyme-linked immunosorbent assay (ELISA).The serum levels of CA125 and CYFRA21-1 were determined by chemiluminescence assay.The results of the 3 biomarkers were analyzed comparatively in different groups,and the positive rates of the 3 individual detections and the combined detection were analyzed.Results Serum HE4,CA125 and CYFRA21-1 levels in malignant ovarian tumor group were significantly higher than those in benign ovarian tumor group and healthy control group (P <0.01).The positive rates of HE4,CA125,CYFRA21-1 and the combined detection of the 3 biomarkers were 88.24%,74.12%,77.65% and 98.82%,respectively.Conclusions The combined detection of HE4,CA125 and CYFRA21-1 shows the good auxiliary diagnosis significance for malignant ovarian tumor.